Request for Free Sample

Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Technology

  2.3.2 Market Size by Product

  2.3.3 Market Size by Cancer Type

  2.3.4 Market Size by End User

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Reagents, Assay Kits, Sequencing Technologies & Biomarker Discovery Suppliers

  3.4.2 Molecular Diagnostic Manufacturers & Bioinformatics Providers

  3.4.3 Pharmaceutical Companies, Clinical Laboratories

  3.4.4 Oncology Centers, Healthcare Providers, Physicians & Cancer Patients

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Companion Diagnostic Technology & Testing Metrics

4.1.1 Share (%) of oncology companion diagnostic demand by NGS, PCR, IHC, in situ hybridization (ISH), and other testing technologies globally.

4.1.2 Growth (%) in comprehensive genomic profiling and biomarker-based cancer testing during 2025 and 2026.

4.1.3 Increase (%) in investments toward precision oncology diagnostics, biomarker discovery, and bioinformatics platforms globally.

4.2 Targeted Therapy & Precision Medicine Metrics

4.2.1 Share (%) of companion diagnostic utilization across targeted therapies, immunotherapies, and personalized oncology treatment programs globally.

4.2.2 Growth (%) in molecular profiling adoption at cancer diagnosis and treatment selection worldwide.

4.2.3 Increase (%) in FDA, EMA, and other regulatory approvals for companion diagnostics linked to oncology drugs globally.

4.3 Liquid Biopsy & Advanced Diagnostic Metrics

4.3.1 Share (%) of oncology companion diagnostic testing performed through liquid biopsy versus tissue-based methods globally.

4.3.2 Growth (%) in ctDNA-based companion diagnostic adoption for treatment monitoring and resistance detection worldwide.

4.3.3 Increase (%) in development and commercialization of minimally invasive cancer diagnostic solutions globally.

4.4 Clinical Trials & Drug Co-Development Metrics

4.4.1 Share (%) of oncology clinical trials incorporating companion diagnostics and biomarker-enriched patient selection globally.

4.4.2 Growth (%) in pharmaceutical-companion diagnostic co-development programs worldwide.

4.4.3 Increase (%) in precision medicine research funding and oncology biomarker validation studies globally.

4.5 Regional Cancer Burden & Healthcare Adoption Metrics

4.5.1 Share (%) of global oncology companion diagnostic demand concentrated across North America, Europe, and Asia Pacific markets.

4.5.2 Growth (%) in cancer incidence, precision medicine adoption, and molecular testing utilization across major healthcare systems.

4.5.3 Increase (%) in healthcare expenditure supporting advanced oncology diagnostics and personalized cancer treatment globally.

5. Oncology Companion Diagnostic Market Analysis & Forecast, By Technology, 2022–2035, Value (USD Billion)

5.1 Introduction

5.2 Polymerase Chain Reaction

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

5.3 Next-Generation Sequencing

5.4 In Situ Hybridization

5.5 Immunohistochemistry

5.6 Others

6. Oncology Companion Diagnostic Market Analysis & Forecast, By Product, 2022–2035, Value (USD Billion)

    6.1 Introduction

    6.2 Assay Kits & Reagents

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Instruments

 6.4 Others

7. Oncology Companion Diagnostic Market Analysis & Forecast, By Cancer Type, 2022–2035, Value (USD Billion)

     7.1 Introduction

 7.2 Non-Small Cell Lung Cancer

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Breast Cancer

 7.4 Colorectal Cancer

 7.5 Melanoma

 7.6 Leukaemia

 7.7 Others

8. Oncology Companion Diagnostic Market Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)

     8.1 Introduction

 8.2 Pharmaceutical & Biopharmaceutical Companies

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 Contract Research Organizations

 8.4 Hospitals & Diagnostic Laboratories

9. Oncology Companion Diagnostic Market Analysis & Forecast, By Region, 2022–2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Oncology Companion Diagnostic Market Size & Forecast, By Technology, 2022–2035

 9.2.3 Oncology Companion Diagnostic Market Size & Forecast, By Product, 2022–2035

 9.2.4 Oncology Companion Diagnostic Market Size & Forecast, By Cancer Type, 2022–2035

 9.2.5 Oncology Companion Diagnostic Market Size & Forecast, By End User, 2022–2035

 9.2.6 Oncology Companion Diagnostic Market Size & Forecast, By Country, 2022–2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Oncology Companion Diagnostic Market Size & Forecast, By Technology, 2022–2035

 9.3.3 Oncology Companion Diagnostic Market Size & Forecast, By Product, 2022–2035

 9.3.4 Oncology Companion Diagnostic Market Size & Forecast, By Cancer Type, 2022–2035

 9.3.5 Oncology Companion Diagnostic Market Size & Forecast, By End User, 2022–2035

 9.3.6 Oncology Companion Diagnostic Market Size & Forecast, By Country, 2022–2035

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Oncology Companion Diagnostic Market Size & Forecast, By Technology, 2022–2035

 9.4.3 Oncology Companion Diagnostic Market Size & Forecast, By Product, 2022–2035

 9.4.4 Oncology Companion Diagnostic Market Size & Forecast, By Cancer Type, 2022–2035

 9.4.5 Oncology Companion Diagnostic Market Size & Forecast, By End User, 2022–2035

 9.4.6 Oncology Companion Diagnostic Market Size & Forecast, By Country, 2022–2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Oncology Companion Diagnostic Market Size & Forecast, By Technology, 2022–2035

 9.5.3 Oncology Companion Diagnostic Market Size & Forecast, By Product, 2022–2035

 9.5.4 Oncology Companion Diagnostic Market Size & Forecast, By Cancer Type, 2022–2035

 9.5.5 Oncology Companion Diagnostic Market Size & Forecast, By End User, 2022–2035

 9.5.6 Oncology Companion Diagnostic Market Size & Forecast, By Country, 2022–2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Oncology Companion Diagnostic Market Size & Forecast, By Technology, 2022–2035

 9.6.3 Oncology Companion Diagnostic Market Size & Forecast, By Product, 2022–2035

 9.6.4 Oncology Companion Diagnostic Market Size & Forecast, By Cancer Type, 2022–2035

 9.6.5 Oncology Companion Diagnostic Market Size & Forecast, By End User, 2022–2035

 9.6.6 Oncology Companion Diagnostic Market Size & Forecast, By Country, 2022–2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 South Africa

  9.6.6.6 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022–2025

  10.2.3 Number Of Strategies Adopted By Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Application Band Benchmarking

  10.4.1 Product/Service Specifications & Features By Key Players

  10.4.2 Product/Service Heatmap By Key Players

  10.4.3 Application Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

 10.6.1 F. Hoffmann-La Roche Ltd.

  10.6.1.1 Company Overview & Snapshot

  10.6.1.2 Product/Service Portfolio

  10.6.1.3 Key Company Financials

  10.6.1.4 SWOT Analysis

10.6.2 QIAGEN N.V.

10.6.3 Thermo Fisher Scientific Inc.

10.6.4 Illumina, Inc.

10.6.5 Agilent Technologies, Inc.

10.6.6 Abbott Laboratories

10.6.7 Bio-Rad Laboratories, Inc.

10.6.8 Guardant Health, Inc.

10.6.9 Exact Sciences Corporation

10.6.10 Myriad Genetics, Inc.

10.6.11 NeoGenomics, Inc.

10.6.12 Foundation Medicine, Inc.

10.6.13 Sysmex Corporation

10.6.14 Natera, Inc.

10.6.15 Invivoscribe, Inc.

10.6.16 Danaher Corporation (Cepheid)

10.6.17 PERSONALIS, Inc.

10.6.18 Adaptive Biotechnologies Corporation

10.6.19 Biocartis Group NV

10.6.20 Genomic Health, Inc. (Exact Sciences)

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List of Tables

 14.2 List of Figures